{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-24-000132","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.416519+00:00","generated_at":"2026-05-30T03:40:32.626031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rallybio Q3 net loss narrows to $11.5M; RLYB212 Phase 2 to screen in Q4","bullets":["Net loss $11.5M ($0.26/share) vs $18.4M ($0.45) in Q3 2023; revenue $0.3M from J&J collaboration.","Cash $75.1M as of Sep 30, 2024 provides runway into mid-2026; R&D expenses down 38% to $8.2M.","RLYB212 Phase 2 CTA approved by EMA and MHRA; screening for pregnant women at FNAIT risk to start Q4 2024.","RLYB116 manufacturing improvements completed; biomarker data suggests potential in PNH and APS beyond myasthenia gravis.","ENPP1 inhibitor candidate nomination with Exscientia on track for Dec 2024; preclinical data showed PPi reduction and improved bone mineralization."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-24-000132","json":"https://secwatch.observer/filing/0001739410-24-000132.json","markdown":"https://secwatch.observer/filing/0001739410-24-000132.md","text":"https://secwatch.observer/filing/0001739410-24-000132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000132/0001739410-24-000132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000132/rlyb-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:40:32.626031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}